Orgonex-Logo
  • Home
  • Product
  • About us
  • Resources
  • Contact
Bart-Spee
  1. Home›
  2. Resources & updates | Orgonex›
  3. The rise of the organoid facility: from craft culture to shared infrastructure
Published on: November 18, 2026

The rise of the organoid facility: from craft culture to shared infrastructure

What is an organoid facility? Learn how organoid core units and centers are turning organoid culture into shared, reproducible research infrastructure.

For a long time, growing organoids has been a craft.

Research groups establish their own models, optimize their own protocols and rely on skilled researchers to keep cultures running. Expansion, passaging, freezing and quality control are often performed by the same scientists who ultimately want to use the organoids in an experiment.

That approach has brought organoid technology remarkably far. But as organoids move into drug discovery, disease modeling, precision medicine, biobanking and biofabrication, the demand for reproducible organoid material is increasing rapidly.

This raises a simple question:
Does every research group really need to grow all of its own organoids?

Increasingly, the answer may be no.

What is an organoid facility?

A new type of research infrastructure is emerging: the organoid facility. Depending on the institution, it may be called an organoid core unit, an organoid center or simply a core facility for organoids. The principle is the same.

Like sequencing cores, imaging facilities or animal facilities, these centralized units bring together specialized equipment, standardized workflows and dedicated expertise to support multiple research groups.

Or, less formally, they are becoming organoid farms.

But their role goes well beyond simply producing large quantities of organoids. A modern organoid facility can support an entire workflow:

Establish → Expand → Characterize → Cryopreserve → Store → Distribute

Some facilities also develop new models, perform genetic engineering, provide training or connect organoid production directly to screening and other downstream applications.

Figure 1. An organoid facility, or organoid core unit, acts as a hub producing and banking organoid models so other research groups don’t have to.

This development is already visible internationally. Dedicated organoid centers and organoid core units are being established that combine model development with quality-controlled expansion, biobanking, automation and distribution. In 2025, the US National Institutes of Health established its Standardized Organoid Modeling Center, specifically aimed at improving the reproducibility and standardization of organoid models.

A recent scientific perspective went even further, calling for dedicated organoid manufacturing, preservation and distribution centers to support the wider research community.

Organoid culture is beginning to become research infrastructure.

From individual cultures to shared resources

Centralization is not only about producing more organoids. It can also help produce them more consistently.

Organoid culture is influenced by many variables, including starting material, passage number, extracellular matrix, medium composition, cell density, timing and operator-dependent handling. When every laboratory independently establishes and maintains its own workflows, these differences can contribute to experimental variability.

A dedicated organoid core facility can build expertise around standardized procedures, predefined quality criteria, traceability and cryopreservation.

This becomes especially valuable when organoid models need to be used by researchers who are not themselves organoid-culture specialists.

A drug discovery group may need repeated batches of a disease model. A bioengineering team may require large numbers of organoids as starting material for tissue construction. A collaborative project may need identical organoid lines distributed across several laboratories.

In each case, separating making the model from using the model can make organoid technology accessible to a much wider research community.

From biobank to living resource

Organoid facilities also fit naturally with the rapid development of organoid biobanks.

A conventional biobank preserves biological samples. An organoid biobank can go one step further by maintaining renewable biological models that can be expanded, characterized, experimentally manipulated, frozen and distributed.

That creates new possibilities, but also new requirements.

A collection of organoid cultures only becomes a reliable research resource when models can be reproducibly expanded, quality controlled and recovered after cryopreservation.

The result is therefore more than a freezer full of organoids.

It is a living, renewable and distributable biological resource.

Scaling out, not just scaling up

When people hear scale-up, they often imagine one increasingly large bioreactor.

For an organoid facility, however, scale often means something different.

A facility may simultaneously maintain dozens or hundreds of patient-derived lines, healthy controls, genetically engineered models or different organoid types. These cultures generally need to remain separate because donor identity and biological characteristics matter.

For organoid facilities, scaling therefore means not only scaling up, but also scaling out.

Figure 2. Scaling out: many donors and models expanded in parallel, each banked and traceable as a separate batch.

Instead of putting everything into one large vessel, multiple independent cultures can be expanded in parallel.

This is where compact, modular bioreactor systems can complement larger automation platforms.

The RPMotion organoid bioreactor uses standard 50 mL tubes to dynamically culture organoids. Multiple cultures can therefore be expanded independently and in parallel, helping organoid centers and core facilities increase production while maintaining separation between donors, models and experimental batches.

This modular approach can provide a bridge between small-scale manual culture and large centralized production workflows.

Making organoids available

The organoid facility of the future may combine technologies that today are still often separated.

A patient sample or stem-cell line enters the facility. A model is established and characterized. Expansion is increasingly standardized and automated. Quality control data are connected to each culture. Validated material enters a cryobank and can subsequently be expanded again and distributed to researchers who need it.

In that sense, the future organoid facility may look less like an individual cell-culture laboratory and more like a combination of a cell factory, biobank and technology core. Some facilities may grow into a full organoid innovation center, where production, model development and new culture technologies come together under one roof.

The goal is not to remove researchers from organoid science.

It is to remove the need for every researcher to become an expert in organoid production.

Organoid research has spent the past decade learning how to create increasingly sophisticated models of human tissues. The next challenge is making those models reproducibly available at the scale research now demands.

Dedicated organoid facilities may become an important part of that transition.

Because the future of organoid research may not depend only on making better organoids.

It may also depend on becoming much better at making organoids available.

Scaling out your organoid facility?

The RPMotion organoid bioreactor lets you expand multiple organoid lines in parallel, each in its own 50 mL tube. With up to 32 bioreactors in a single incubator, donors, models and batches stay separate as your production grows.

Discover the RPMotion →

About the author

Bart-Spee

Bart Spee, PhD — Co-founder, Orgonex
Bart co-founded Orgonex out of Utrecht University, where his research on liver organoid biobanking and bioreactor-based expansion underpins the RPMotion platform.

Read more about the team

Orgonex-Logo
ProductAbout usContactNews

Universiteitsweg 101
3584 CG
Utrecht

Registered at the Dutch Chamber of Commerce under no. 88954870

Orgonex is part of the Demcon group
Cookie policyPrivacy statement
© 2026 Demcon. All rights reserved.